Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development
- 1 April 2004
- journal article
- review article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 40 (6), 837-844
- https://doi.org/10.1016/j.ejca.2004.01.003
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Physiologically Based Pharmacokinetic (PBPK) Modeling of Disposition of Epiroprim in HumansJournal of Pharmaceutical Sciences, 2003
- Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesisNature Medicine, 2002
- Interspecies Pharmacokinetic Comparisons and Allometric Scaling of Napsagatran, a Low Molecular Weight Thrombin InhibitorJournal of Pharmacy and Pharmacology, 1999
- Relationship Between Topotecan Systemic Exposure and Tumor Response in Human Neuroblastoma XenograftsJNCI Journal of the National Cancer Institute, 1998
- Targeted expression of MYCN causes neuroblastoma in transgenic miceThe EMBO Journal, 1997
- Therapeutic efficacy of the cyclopropylpyrroloindole, carzelesin, against xenografts derived from adult and childhood solid tumorsCancer Chemotherapy and Pharmacology, 1995
- Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancersCancer Chemotherapy and Pharmacology, 1994
- The allometric approach for interspecies scaling of pharmacokinetic parametersComparative Biochemistry and Physiology Part C: Comparative Pharmacology, 1992
- Dosage Regimen Design for Pharmaceutical Studies Conducted in AnimalsJournal of Pharmaceutical Sciences, 1986
- Childhood rhabdomyosarcoma xenografts: Responses to DNA-interacting agents and agents used in current clinical therapyEuropean Journal of Cancer and Clinical Oncology, 1984